4.7 Article

Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis?

Journal

JOURNAL OF INFECTION
Volume 65, Issue 3, Pages 262-268

Publisher

W B SAUNDERS CO LTD
DOI: 10.1016/j.jinf.2012.05.001

Keywords

Aspergillus; Pulmonary; Coinfection; Immunocompromised; Hematologic

Funding

  1. Pfizer
  2. Astellas Pharma US
  3. Gilead Inc
  4. Merck and Co., Inc.
  5. National Institutes of Health through MD Anderson's Cancer Center [CA016672]
  6. Frances King Black Endowment

Ask authors/readers for more resources

Background: Immunocompromised patients with hematological malignancies and/or recipients of hematopoietic stem cell transplants are constantly exposed to several fungal, bacterial, and viral respiratory pathogens. Methods: We retrospectively evaluated all patients with invasive pulmonary aspergillosis (IPA) and underlying hematological malignancies for the presence of concurrent, microbiologically documented pulmonary infections during a 5-year period (2005-2010). Results: We found 126 such patients that frequently had coinfections (49%) with respiratory pathogens other than Aspergillus species, with a higher rate in patients with probable IPA (53%) than in those with proven IPA (29%; P=0.038). Conclusions: As the majority of patients with IPA in daily practice have probable IPA, often according to only the combination of positivity for serological biomarkers and radiological findings, our data may raise skepticism about both the certainty of IPA diagnosis and the evaluation of response to antifungals in a subset of these patients. (C) 2012 Published by Elsevier Ltd on behalf of The British Infection Association.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available